A Phase 2 interventional study of LEO 29102 cream and LEO 29102 Cream Vehicle in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.
Sponsored by LEO Pharma · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing betamethasone dipropionate in Psoriasis — 1 open to participants now, 1 under way, 1 of them phase 3. betamethasone dipropionate · Psoriasis.
Among the 29 studies testing betamethasone dipropionate in Psoriasis, this one is the 27th largest by enrollment, is one of 2 that started in 2009, is one of 9 in phase 2, and was the 9th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 29 studies testing betamethasone dipropionate in Psoriasis is open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 18+
By country, each count listing its studies:
betamethasone dipropionate: first FDA approval 1975 (DIPROSONE). What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 11 · Phase 4 7
First in 2004; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 224 across the 29 interventional studies. Of the 27 that completed or were terminated, 15 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 29 have an industry lead sponsor. The 10 most frequent:
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
79 studies in Psoriasis by LEO Pharma: 1 open now, 2 under way, none of them phase 3. Of 77 finished, 36 (47%) have results posted.
Among the 79 studies in Psoriasis by LEO Pharma, this one is the 55th largest by enrollment of the 71 interventional ones that give a count, is one of 5 that started in 2009, is one of 24 in phase 2, and was the 17th registered.
LEO Pharma’s Psoriasis studies by the year they started, since 2004.
1 of the studies testing betamethasone dipropionate in Psoriasis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies testing betamethasone dipropionate in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among LEO Pharma’s 79 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to evaluate the anti-psoriatic effect of LEO 29102 cream and its combination with calcipotriol and betamethasone using a psoriasis plaque test method.
Inclusion Criteria: (in summary)
Exclusion Criteria: (in summary)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks
Drug: LEO 29102 cream
LEO 29102 cream vehicle applied topically twice daily for 4 weeks.
Drug: LEO 29102 Cream Vehicle
Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.
Drug: Betamethasone Dipropionate Cream
LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.
Drug: LEO 29102 Plus Calcipotriol Cream
LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.
Drug: LEO 29102 Plus Betamethasone Dipropionate
Daivobet® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.
Drug: Daivobet® Ointment
Drug pages: 2-(6-(2-(3,5-dichloro-4-pyridyl)acetyl)-2,3-dimethoxyphenoxy)-N-propylacetamide · Calcipotriene
Drug pages: 2-(6-(2-(3,5-dichloro-4-pyridyl)acetyl)-2,3-dimethoxyphenoxy)-N-propylacetamide · Betamethasone dipropionate
Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1)
The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).
Time frame: From baseline (Day 1) to end of treatment (Day 29)
Change in Single Clinical Symptom Score: Erythema, Scaling, Infiltration Compared to Baseline
The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).
Time frame: From baseline (Day 1) to end of treatment (Day 29)
Change in Erythema Compared to Baseline
The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale. The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red
Time frame: At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22 and Day 25
Change in Scaling Compared to Baseline
The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale. The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales
Time frame: At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25
Change in Infiltration Compared to Baseline
The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale. The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration
Time frame: At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25
Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline
The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).
Time frame: At Day 4, Day 8, Day 11, Day 15, Day 18, Day 22, and Day 25
Ultrasonography: Change in Lesions Thickness From Baseline Measured by Ultrasound
The lesion thickness was measured by ultrasound at baseline, Day 8, Day 15, Day 22 and end of treatment.
Time frame: At Day 8, Day 15, Day 22 and end of treatment
Biomarkers by Immunochemistry
3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement. Cells counted per mm\^2 were cells that were positive for the indicated biomarker.
Time frame: At end of treatment
Biomarkers by Immunochemistry: Epidermal Differentiation
3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement.
Time frame: At end of treatment
Biomarkers by Immunochemistry: Epidermal Proliferation
3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement. By measurement of the cell-cycle marker, Ki-67 protein, an evaluation of the degree of skin cell proliferation and thereby epidermal proliferation could be obtained. Cells counted per mm\^2 were cells that were positive for the indicated biomarker.
Time frame: At end of treatment
Pathology and Histology by Treatment
Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. The extent of the following parameters were measured in scored semi-quantitatively (semi) on blinded haematoxylin and eosin (HE) sections. Semi-quantitative scoring was categorized as No (0), mild (1), moderate (2), marked (3) or severe (4). In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum) the tissue was classified by the characteristics seen below: * Morphology of epidermis * Stratum corneum (semi (extent of)) * Stratum granulosum (semi (extent of)) * Parakeratosis (semi (extent of)) * Infiltration of inflammatory cells (semi (extent of))
Time frame: At end of treatment
Pathology and Histology by Treatment: Epidermal Thickness
Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum), the tissue was classified by the characteristic epidermal thickness. This was measured in the absolute number of µm measured on blinded haematoxylin and eosin (HE) sections..
Time frame: At end of treatment
Pathology and Histology by Treatment: Frequency of Neutrophil Abscesses
Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum), the tissue was classified by the characteristic of frequency of neutrophil microabscesses (Monroe´s abscess). This was measured in absolute number of cells that were positive for the marker on blinded haematoxylin and eosin (HE) sections.
Time frame: At end of treatment
Participants were treated with the investigational medicinal products for 4 weeks followed by a 10-day follow-up period.
| Milestone | All Randomized Participants |
|---|---|
| Started | 24 |
| Completed | 24 |
| Not completed | 0 |
The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).
| score on a scale | LEO 29102 Cream Vehicle | Betamethasone Dipropionate Cream | LEO 29102 Cream | LEO 29102 Plus Calcipotriol Cream | LEO 29102 Plus Betamethasone Dipropionate | Daivobet® Ointment |
|---|---|---|---|---|---|---|
| Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1) | -1.60 ± 1.18 | -4.96 ± 1.99 | -3.04 ± 1.34 | -3.96 ± 1.49 | -5.56 ± 1.28 | -6.10 ± 1.06 |
The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).
| score on a scale | LEO 29102 Cream Vehicle | Betamethasone Dipropionate Cream | LEO 29102 Cream | LEO 29102 Plus Calcipotriol Cream | LEO 29102 Plus Betamethasone Dipropionate | Daivobet® Ointment |
|---|---|---|---|---|---|---|
| Erythema | -0.42 ± 0.48 | -1.71 ± 0.81 | -0.90 ± 0.55 | -1.19 ± 0.70 | -1.85 ± 0.63 | -1.88 ± 0.45 |
| Infiltration | -0.46 ± 0.33 | -1.46 ± 0.75 | -0.85 ± 0.52 | -1.17 ± 0.50 | -1.75 ± 0.53 | -2.04 ± 0.55 |
| Scaliness | -0.73 ± 0.57 | -1.79 ± 0.62 | -1.29 ± 0.51 | -1.60 ± 0.55 | -1.96 ± 0.41 | -2.19 ± 0.41 |
The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale. The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red
| units on a scale | LEO 29102 Cream Vehicle | Betamethasone Dipropionate Cream | LEO 29102 Cream | LEO 29102 Plus Calcipotriol Cream | LEO 29102 Plus Betamethasone Dipropionate | Daivobet® Ointment |
|---|---|---|---|---|---|---|
| Visit 5 (Day 4) | -0.04 ± 0.25 | -0.21 ± 0.29 | -0.02 ± 0.18 | -0.08 ± 0.24 | -0.40 ± 0.42 | -0.38 ± 0.42 |
| Visit 8 (Day 8) | -0.08 ± 0.38 | -0.67 ± 0.46 | -0.31 ± 0.32 | -0.29 ± 0.29 | -0.92 ± 0.43 | -0.88 ± 0.56 |
| Visit 11 (Day 11) | -0.23 ± 0.33 | -0.94 ± 0.47 | -0.46 ± 0.33 | -0.44 ± 0.37 | -1.17 ± 0.43 | -1.19 ± 0.66 |
| Visit 14 (Day 15) | -0.40 ± 0.36 | -1.23 ± 0.69 | -0.60 ± 0.36 | -0.77 ± 0.42 | -1.46 ± 0.59 | -1.40 ± 0.66 |
| Visit 17 (Day 18) | -0.44 ± 0.40 | -1.33 ± 0.76 | -0.75 ± 0.42 | -0.98 ± 0.40 | -1.71 ± 0.61 | -1.63 ± 0.56 |
| Visit 20 (Day 22) | -0.46 ± 0.49 | -1.48 ± 0.80 | -0.83 ± 0.55 | -1.04 ± 0.51 | -1.75 ± 0.66 | -1.85 ± 0.60 |
| Visit 23 (Day 25) | -0.42 ± 0.43 | -1.54 ± 0.81 | -0.85 ± 0.54 | -1.08 ± 0.50 | -1.83 ± 0.72 | -1.94 ± 0.54 |
The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale. The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales
| units on a scale | LEO 29102 Cream Vehicle | Betamethasone Dipropionate Cream | LEO 29102 Cream | LEO 29102 Plus Calcipotriol Cream | LEO 29102 Plus Betamethasone Dipropionate | Daivobet® Ointment |
|---|---|---|---|---|---|---|
| Visit 5 (Day 4) | -0.17 ± 0.35 | -0.31 ± 0.41 | -0.13 ± 0.30 | -0.21 ± 0.41 | -0.33 ± 0.43 | -0.52 ± 0.38 |
| Visit 8 (Day 8) | -0.27 ± 0.42 | -0.88 ± 0.61 | -0.44 ± 0.58 | -0.63 ± 0.58 | -1.17 ± 0.67 | -1.19 ± 0.48 |
| Visit 11 (Day 11) | -0.40 ± 0.33 | -1.15 ± 0.54 | -0.63 ± 0.42 | -0.71 ± 0.61 | -1.48 ± 0.58 | -1.92 ± 0.55 |
| Visit 14 (Day 15) | -0.52 ± 0.52 | -1.33 ± 0.64 | -0.73 ± 0.47 | -1.00 ± 0.55 | -1.67 ± 0.58 | -2.04 ± 0.49 |
| Visit 17 (Day 18) | -0.65 ± 0.45 | -1.56 ± 0.60 | -0.90 ± 0.47 | -1.15 ± 0.54 | -1.83 ± 0.58 | -2.13 ± 0.49 |
| Visit 20 (Day 22) | -0.54 ± 0.29 | -1.54 ± 0.62 | -0.81 ± 0.44 | -1.27 ± 0.42 | -1.75 ± 0.53 | -2.19 ± 0.38 |
| Visit 23 (Day 25) | -0.75 ± 0.42 | -1.81 ± 0.60 | -1.17 ± 0.55 | -1.46 ± 0.57 | -2.00 ± 0.42 | -2.21 ± 0.36 |
The severity of the symptoms was rated on screening and on study Days 1 (baseline), 4, 8, 11, 15, 18, 22, 25 and 29 (end of treatment) according to the 0-3 with half-point TCS grading scale. The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration
| units on a scale | LEO 29102 Cream Vehicle | Betamethasone Dipropionate Cream | LEO 29102 Cream | LEO 29102 Plus Calcipotriol Cream | LEO 29102 Plus Betamethasone Dipropionate | Daivobet® Ointment |
|---|---|---|---|---|---|---|
| Visit 5 (Day 4) | -0.06 ± 0.27 | -0.10 ± 0.29 | -0.04 ± 0.20 | 0.00 ± 0.21 | -0.27 ± 0.25 | -0.29 ± 0.33 |
| Visit 8 (Day 8) | -0.06 ± 0.31 | -0.38 ± 0.34 | -0.13 ± 0.34 | -0.29 ± 0.51 | -0.73 ± 0.47 | -0.79 ± 0.44 |
| Visit 11 (Day 11) | -0.13 ± 0.37 | -0.77 ± 0.51 | -0.31 ± 0.38 | -0.46 ± 0.39 | -1.06 ± 0.50 | -1.29 ± 0.62 |
| Visit 14 (Day 15) | -0.25 ± 0.33 | -0.98 ± 0.60 | -0.42 ± 0.43 | -0.69 ± 0.38 | -1.35 ± 0.65 | -1.79 ± 0.59 |
| Visit 17 (Day 18) | -0.33 ± 0.35 | -1.10 ± 0.61 | -0.58 ± 0.46 | -0.75 ± 0.39 | -1.50 ± 0.63 | -1.94 ± 0.61 |
| Visit 20 (Day 22) | -0.31 ± 0.29 | -1.25 ± 0.66 | -0.56 ± 0.47 | -0.90 ± 0.33 | -1.67 ± 0.62 | -1.98 ± 0.52 |
| Visit 23 (Day 25) | -0.38 ± 0.34 | -1.35 ± 0.73 | -0.73 ± 0.47 | -1.06 ± 0.40 | -1.67 ± 0.60 | -2.02 ± 0.54 |
The (sub)investigator made the following clinical assessments by use of the scale below: Score; Intensity; Description Erythema: 0; No evidence; Normal skin color 0.5; Doubtful or very mild 1.0; Mild; Pink light red 1.5; Mild to moderate 2.0; Moderate; Red 2.5; Moderate to severe 3.0; Severe; Intense red Scaling: 0; No evidence; No scaling 0.5; Doubtful or very mild 1.0; Mild; Slight roughness, mainly fine scales 1.5; Mild to moderate 2.0; Moderate; Coarse scaling 2.5; Moderate to severe 3.0; Severe; Coarse, thick scales Infiltration: 0; No evidence 0.5; Doubtful or very mild 1.0; Mild Slight definite infiltration 1.5; Mild to moderate 2.0; Moderate; Moderate infiltration 2.5; Moderate to severe 3.0; Severe; Very marked infiltration The TCS was defined as the sum of erythema plus scaling plus thickness scores. The TCS therefore ranged from 0 (all symptoms absent) to 9 (all symptoms severe).
| score on a scale | LEO 29102 Cream Vehicle | Betamethasone Dipropionate Cream | LEO 29102 Cream | LEO 29102 Plus Calcipotriol Cream | LEO 29102 Plus Betamethasone Dipropionate | Daivobet® Ointment |
|---|---|---|---|---|---|---|
| Visit 5 (Day 4) | -0.27 ± 0.66 | -0.63 ± 0.80 | -0.19 ± 0.53 | -0.29 ± 0.66 | -1.00 ± 0.88 | -1.19 ± 0.86 |
| Visit 8 (Day 8) | -0.42 ± 0.78 | -1.92 ± 1.18 | -0.88 ± 0.97 | -1.21 ± 1.07 | -2.81 ± 1.26 | -2.85 ± 1.17 |
| Visit 11 (Day 11) | -0.75 ± 0.75 | -2.85 ± 1.26 | -1.40 ± 0.90 | -1.60 ± 1.11 | -3.71 ± 1.28 | -4.40 ± 1.42 |
| Visit 14 (Day 15) | -1.17 ± 0.89 | -3.54 ± 1.66 | -1.75 ± 1.12 | -2.46 ± 1.00 | -4.48 ± 1.56 | -5.23 ± 1.41 |
| Visit 17 (Day 18) | -1.42 ± 0.95 | -4.00 ± 1.72 | -2.23 ± 1.11 | -2.88 ± 0.99 | -5.04 ± 1.46 | -5.69 ± 1.30 |
| Visit 20 (Day 22) | -1.31 ± 0.83 | -4.27 ± 1.92 | -2.21 ± 1.20 | -3.21 ± 0.98 | -5.17 ± 1.64 | -6.02 ± 1.08 |
| Visit 23 (Day 25) | -1.54 ± 0.97 | -4.71 ± 1.99 | -2.75 ± 1.32 | -3.60 ± 1.25 | -5.50 ± 1.47 | -6.17 ± 0.87 |
The lesion thickness was measured by ultrasound at baseline, Day 8, Day 15, Day 22 and end of treatment.
| mm | LEO 29102 Cream Vehicle | Betamethasone Dipropionate Cream | LEO 29102 Cream | LEO 29102 Plus Calcipotriol Cream | LEO 29102 Plus Betamethasone Dipropionate | Daivobet® Ointment |
|---|---|---|---|---|---|---|
| Visit 8 (Day 8) | 0.05 ± 0.22 | -0.14 ± 0.32 | 0.03 ± 0.24 | 0.00 ± 0.24 | -0.30 ± 0.27 | -0.39 ± 0.30 |
| Visit 14 (Day 15) | -0.05 ± 0.23 | -0.45 ± 0.39 | -0.16 ± 0.31 | -0.25 ± 0.36 | -0.51 ± 0.32 | -0.68 ± 0.46 |
| Visit 20 (Day 22) | -0.07 ± 0.27 | -0.54 ± 0.37 | -0.15 ± 0.19 | -0.24 ± 0.32 | -0.57 ± 0.34 | -0.68 ± 0.39 |
| Visit 26 (Day 29) | -0.13 ± 0.30 | -0.63 ± 0.39 | -0.30 ± 0.31 | -0.38 ± 0.30 | -0.68 ± 0.34 | -0.78 ± 0.43 |
3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement. Cells counted per mm\^2 were cells that were positive for the indicated biomarker.
| cells/mm^2 | LEO 29102 Cream Vehicle | Betamethasone Dipropionate Cream | LEO 29102 Cream | LEO 29102 Plus Calcipotriol Cream | LEO 29102 Plus Betamethasone Dipropionate | Daivobet® Ointment |
|---|---|---|---|---|---|---|
| Macrophages: CD163 | 313.9 ± 97.28 | 197.4 ± 69.51 | 291.2 ± 100.8 | 383.5 ± 488.6 | 178.2 ± 27.96 | 172.9 ± 40.61 |
| Dendritic cells CD1a | 233.8 ± 113.9 | 42.14 ± 27.81 | 229.3 ± 134.2 | 244.0 ± 118.9 | 34.31 ± 20.00 | 56.34 ± 33.81 |
| T-cell biomarker CD3 | 593.8 ± 243.9 | 124.5 ± 105.9 | 464.2 ± 275.9 | 492.7 ± 280.4 | 126.1 ± 95.57 | 143.9 ± 161.5 |
| Angiogenesis: CD31 | 430.7 ± 165.7 | 216.3 ± 100.1 | 331.1 ± 120.9 | 348.8 ± 158.1 | 184.2 ± 38.84 | 186.6 ± 51.62 |
| T-cell biomarker: CD4 | 284.3 ± 123.9 | 59.17 ± 41.78 | 246.4 ± 148.0 | 239.0 ± 147.3 | 55.56 ± 44.03 | 66.95 ± 55.07 |
| T-cell biomarker: CD45RO | 752.0 ± 183.1 | 101.6 ± 78.14 | 630.1 ± 318.8 | 643.6 ± 370.4 | 121.6 ± 50.39 | 218.2 ± 258.7 |
| Macrophages: CD68 | 370.8 ± 58.56 | 120.3 ± 61.57 | 323.1 ± 114.2 | 303.8 ± 117.8 | 142.1 ± 58.47 | 156.8 ± 44.82 |
| T-cell biomarker: CD8 | 280.5 ± 156.0 | 60.05 ± 61.95 | 220.7 ± 123.9 | 253.2 ± 171.9 | 66.35 ± 53.30 | 65.05 ± 72.00 |
3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement.
| %, positive area/total area | LEO 29102 Cream Vehicle | Betamethasone Dipropionate Cream | LEO 29102 Cream | LEO 29102 Plus Calcipotriol Cream | LEO 29102 Plus Betamethasone Dipropionate | Daivobet® Ointment |
|---|---|---|---|---|---|---|
| Epidermal differentiation: CK10 | 0.76 ± 0.14 | 0.89 ± 0.15 | 0.77 ± 0.14 | 0.75 ± 0.11 | 0.93 ± 0.08 | 0.89 ± 0.25 |
| Epidermal differentiation: CK16 | 0.11 ± 0.14 | 0.00 ± 0.00 | 0.08 ± 0.11 | 0.02 ± 0.04 | 0.01 ± 0.01 | 0.00 ± 0.01 |
3 skin biopsies (punch biopsies of 3 mm) per participant were taken on Day 29 after the clinical scoring and ultrasound measurement. By measurement of the cell-cycle marker, Ki-67 protein, an evaluation of the degree of skin cell proliferation and thereby epidermal proliferation could be obtained. Cells counted per mm\^2 were cells that were positive for the indicated biomarker.
| cells/mm^2 | LEO 29102 Cream Vehicle | Betamethasone Dipropionate Cream | LEO 29102 Cream | LEO 29102 Plus Calcipotriol Cream | LEO 29102 Plus Betamethasone Dipropionate | Daivobet® Ointment |
|---|---|---|---|---|---|---|
| Biomarkers by Immunochemistry: Epidermal Proliferation | 554.1 ± 391.9 | 19.45 ± 28.69 | 443.3 ± 298.6 | 354.3 ± 198.2 | 20.50 ± 29.11 | 93.49 ± 134.9 |
Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. The extent of the following parameters were measured in scored semi-quantitatively (semi) on blinded haematoxylin and eosin (HE) sections. Semi-quantitative scoring was categorized as No (0), mild (1), moderate (2), marked (3) or severe (4). In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum) the tissue was classified by the characteristics seen below: * Morphology of epidermis * Stratum corneum (semi (extent of)) * Stratum granulosum (semi (extent of)) * Parakeratosis (semi (extent of)) * Infiltration of inflammatory cells (semi (extent of))
| score on a scale | LEO 29102 Cream Vehicle | Betamethasone Dipropionate Cream | LEO 29102 Cream | LEO 29102 Plus Calcipotriol Cream | LEO 29102 Plus Betamethasone Dipropionate | Daivobet® Ointment |
|---|---|---|---|---|---|---|
| Infiltration of inflammatory cells | 1.50 ± 0.80 | 0.17 ± 0.41 | 1.52 ± 0.79 | 1.53 ± 0.94 | 0.50 ± 0.55 | 0.67 ± 1.03 |
| Parakeratosis | 1.67 ± 1.15 | 0.00 ± 0.00 | 1.39 ± 1.34 | 1.35 ± 1.11 | 0.00 ± 0.00 | 0.17 ± 0.41 |
| Stratum Corneum | 1.83 ± 0.83 | 0.33 ± 0.52 | 1.52 ± 0.90 | 1.41 ± 0.94 | 0.50 ± 0.55 | 0.33 ± 0.82 |
| Stratum Granulosum | 1.42 ± 1.24 | 0.17 ± 0.41 | 1.04 ± 1.26 | 1.00 ± 1.17 | 0.00 ± 0.00 | 0.17 ± 0.41 |
Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum), the tissue was classified by the characteristic epidermal thickness. This was measured in the absolute number of µm measured on blinded haematoxylin and eosin (HE) sections..
| µm | LEO 29102 Cream Vehicle | Betamethasone Dipropionate Cream | LEO 29102 Cream | LEO 29102 Plus Calcipotriol Cream | LEO 29102 Plus Betamethasone Dipropionate | Daivobet® Ointment |
|---|---|---|---|---|---|---|
| Pathology and Histology by Treatment: Epidermal Thickness | 254.6 ± 58.68 | 73.81 ± 20.61 | 187.5 ± 79.65 | 176.4 ± 49.05 | 68.48 ± 18.16 | 66.90 ± 44.53 |
Skin biopsies were taken on Day 29. The evaluation of immunohistochemical sections were performed on cross sections of the skin tissue. The same pathologist did all evaluations, and samples were masked to ensure a blind fashion study. In evaluating the morphology of epidermis (Stratum corneum and Stratum granulosum), the tissue was classified by the characteristic of frequency of neutrophil microabscesses (Monroe´s abscess). This was measured in absolute number of cells that were positive for the marker on blinded haematoxylin and eosin (HE) sections.
| cells/mm^2 | LEO 29102 Cream Vehicle | Betamethasone Dipropionate Cream | LEO 29102 Cream | LEO 29102 Plus Calcipotriol Cream | LEO 29102 Plus Betamethasone Dipropionate | Daivobet® Ointment |
|---|---|---|---|---|---|---|
| Pathology and Histology by Treatment: Frequency of Neutrophil Abscesses | 0.14 ± 0.26 | 0.00 ± 0.00 | 0.15 ± 0.35 | 0.17 ± 0.30 | 0.00 ± 0.00 | 0.05 ± 0.13 |
Collected over From baseline to end of Follow-up (Day 43±2). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Randomized Participants | — | 0/24 (0%) | 8/24 (33.3%) |
| Event | All Randomized Participants |
|---|---|
| HeadacheNervous system disorders | 4/24 |
| DiarrhoeaGastrointestinal disorders | 3/24 |
| DiverticulitisGastrointestinal disorders | 1/24 |
| ToothacheGastrointestinal disorders | 1/24 |
| HordeolumInfections and infestations | 1/24 |
| NasopharyngitisInfections and infestations | 1/24 |
| Postoperative infectionInfections and infestations | 1/24 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/24 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/24 |
| Age, Continuous(years) | All Randomized Participants |
|---|---|
| Mean | 50.7 ± 12.8 |
| Sex: Female, Male(Participants) | All Randomized Participants |
|---|---|
| Female | 6 |
| Male | 18 |
| Region of Enrollment(participants) | All Randomized Participants |
|---|---|
| France | 24 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Apr 2009, a primary completion of May 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2019, 10 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: 2-(6-(2-(3,5-dichloro-4-pyridyl)acetyl)-2,3-dimethoxyphenoxy)-N-propylacetamide · Betamethasone dipropionate · Calcipotriene